3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
45
Carcinoma, Non-Small-Cell Lung
2
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Recurrence
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Inflammatory Breast Neoplasms
1
HER2 Positive Breast Cancer
1
Genomic Instability
1
Cholangiocarcinoma
1
Breast Cancer Metastatic
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
tucatinib
1
pralsetinib
1
pertuzumab
1
ipatasertib
1
inavolisib
1
entrectinib
1
atezolizumab
1
alectinib
1
Trastuzumab
1
Tiragolumab
1
Paclitaxel
1
Ado-Trastuzumab Emtansine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Advanced Unresectable or Metastatic Solid Malignancy
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT04632992
2025-01-08
MyTACTIC
Genentech, Inc.
Phase 2
Completed
252 enrolled
27 charts